Sanara Medtech Inc

SMTI is in a clear Stage 2 advance, trading just below its 52-week high with the 9-, 20-, 50-day, and 200-day moving averages aligned bullishly. The active Lockout Rally and Parabola patterns reflect forced repricing and steep trend acceleration, overriding typical overbought concerns. As a result, timing conditions favor immediate continuation participation (Buy Now) above the rising EMA zone. The medium-term bias remains bullish under the Momentum + EPS strategy, with primary risk centered on a sharp reversal if the 9- or 20-day EMA fails.

• ↑Consensus FY25 EPS forecast improved from -$1.56 to -$0.98
• ↑Agreement to acquire MiMedx expands surgical wound portfolio and synergy potential
• ↓Negative earnings yield and low book-to-price factors signal overvaluation